Acute overdosage of large doses of oral contraceptives in chidren reportedly produces almost no toxicity except nausea and vomiting. Acute overdosage of estrogens may cause nausea, and withdrawal bleeding may occur in females.
A powerful synthetic, non-steroidal estrogen. PubChem
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Prasterone | The risk or severity of adverse effects can be increased when Prasterone is combined with Chlorotrianisene. |
| Exemestane | The therapeutic efficacy of Exemestane can be decreased when used in combination with Chlorotrianisene. |
| Hyaluronidase (ovine) | The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Chlorotrianisene. |
| Hyaluronidase (human recombinant) | The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Chlorotrianisene. |
| Hyaluronidase | The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Chlorotrianisene. |
| Lenalidomide | Chlorotrianisene may increase the thrombogenic activities of Lenalidomide. |
| Ospemifene | The risk or severity of adverse effects can be increased when Chlorotrianisene is combined with Ospemifene. |
| Ropinirole | Chlorotrianisene may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy. |
| Thalidomide | Chlorotrianisene may increase the thrombogenic activities of Thalidomide. |
| Cetuximab | Chlorotrianisene may increase the thrombogenic activities of Cetuximab. |
| Human immunoglobulin G | Chlorotrianisene may increase the thrombogenic activities of Human immunoglobulin G. |
| Omalizumab | Chlorotrianisene may increase the thrombogenic activities of Omalizumab. |
| Adalimumab | Chlorotrianisene may increase the thrombogenic activities of Adalimumab. |
| Gemtuzumab ozogamicin | Chlorotrianisene may increase the thrombogenic activities of Gemtuzumab ozogamicin. |
| Indium In-111 satumomab pendetide | Chlorotrianisene may increase the thrombogenic activities of Indium In-111 satumomab pendetide. |
| Infliximab | Chlorotrianisene may increase the thrombogenic activities of Infliximab. |
| Trastuzumab | Chlorotrianisene may increase the thrombogenic activities of Trastuzumab. |
| Rituximab | Chlorotrianisene may increase the thrombogenic activities of Rituximab. |
| Basiliximab | Chlorotrianisene may increase the thrombogenic activities of Basiliximab. |
| Muromonab | Chlorotrianisene may increase the thrombogenic activities of Muromonab. |
| Digoxin Immune Fab (Ovine) | Chlorotrianisene may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Ibritumomab tiuxetan | Chlorotrianisene may increase the thrombogenic activities of Ibritumomab tiuxetan. |
| Tositumomab | Chlorotrianisene may increase the thrombogenic activities of Tositumomab. |
| Alemtuzumab | Chlorotrianisene may increase the thrombogenic activities of Alemtuzumab. |
| Capromab pendetide | Chlorotrianisene may increase the thrombogenic activities of Capromab pendetide. |
| Efalizumab | Chlorotrianisene may increase the thrombogenic activities of Efalizumab. |
| Antithymocyte immunoglobulin (rabbit) | Chlorotrianisene may increase the thrombogenic activities of Antithymocyte immunoglobulin (rabbit). |
| Natalizumab | Chlorotrianisene may increase the thrombogenic activities of Natalizumab. |
| Palivizumab | Chlorotrianisene may increase the thrombogenic activities of Palivizumab. |
| Daclizumab | Chlorotrianisene may increase the thrombogenic activities of Daclizumab. |
| Bevacizumab | Chlorotrianisene may increase the thrombogenic activities of Bevacizumab. |
| Technetium Tc-99m arcitumomab | Chlorotrianisene may increase the thrombogenic activities of Technetium Tc-99m arcitumomab. |
| Eculizumab | Chlorotrianisene may increase the thrombogenic activities of Eculizumab. |
| Panitumumab | Chlorotrianisene may increase the thrombogenic activities of Panitumumab. |
| Ranibizumab | Chlorotrianisene may increase the thrombogenic activities of Ranibizumab. |
| Galiximab | Chlorotrianisene may increase the thrombogenic activities of Galiximab. |
| Pexelizumab | Chlorotrianisene may increase the thrombogenic activities of Pexelizumab. |
| Afelimomab | Chlorotrianisene may increase the thrombogenic activities of Afelimomab. |
| Epratuzumab | Chlorotrianisene may increase the thrombogenic activities of Epratuzumab. |
| Bectumomab | Chlorotrianisene may increase the thrombogenic activities of Bectumomab. |
| Oregovomab | Chlorotrianisene may increase the thrombogenic activities of Oregovomab. |
| IGN311 | Chlorotrianisene may increase the thrombogenic activities of IGN311. |
| Adecatumumab | Chlorotrianisene may increase the thrombogenic activities of Adecatumumab. |
| Labetuzumab | Chlorotrianisene may increase the thrombogenic activities of Labetuzumab. |
| Matuzumab | Chlorotrianisene may increase the thrombogenic activities of Matuzumab. |
| Fontolizumab | Chlorotrianisene may increase the thrombogenic activities of Fontolizumab. |
| Bavituximab | Chlorotrianisene may increase the thrombogenic activities of Bavituximab. |
| CR002 | Chlorotrianisene may increase the thrombogenic activities of CR002. |
| Rozrolimupab | Chlorotrianisene may increase the thrombogenic activities of Rozrolimupab. |
| Girentuximab | Chlorotrianisene may increase the thrombogenic activities of Girentuximab. |
| Obiltoxaximab | Chlorotrianisene may increase the thrombogenic activities of Obiltoxaximab. |
| XTL-001 | Chlorotrianisene may increase the thrombogenic activities of XTL-001. |
| NAV 1800 | Chlorotrianisene may increase the thrombogenic activities of NAV 1800. |
| Briakinumab | Chlorotrianisene may increase the thrombogenic activities of Briakinumab. |
| Otelixizumab | Chlorotrianisene may increase the thrombogenic activities of Otelixizumab. |
| AMG 108 | Chlorotrianisene may increase the thrombogenic activities of AMG 108. |
| Iratumumab | Chlorotrianisene may increase the thrombogenic activities of Iratumumab. |
| Enokizumab | Chlorotrianisene may increase the thrombogenic activities of Enokizumab. |
| Ramucirumab | Chlorotrianisene may increase the thrombogenic activities of Ramucirumab. |
| Farletuzumab | Chlorotrianisene may increase the thrombogenic activities of Farletuzumab. |
| Veltuzumab | Chlorotrianisene may increase the thrombogenic activities of Veltuzumab. |
| Ustekinumab | Chlorotrianisene may increase the thrombogenic activities of Ustekinumab. |
| Trastuzumab emtansine | Chlorotrianisene may increase the thrombogenic activities of Trastuzumab emtansine. |
| PRO-542 | Chlorotrianisene may increase the thrombogenic activities of PRO-542. |
| TNX-901 | Chlorotrianisene may increase the thrombogenic activities of TNX-901. |
| Inotuzumab ozogamicin | Chlorotrianisene may increase the thrombogenic activities of Inotuzumab ozogamicin. |
| RI 624 | Chlorotrianisene may increase the thrombogenic activities of RI 624. |
| Stamulumab | Chlorotrianisene may increase the thrombogenic activities of MYO-029. |
| CT-011 | Chlorotrianisene may increase the thrombogenic activities of CT-011. |
| Leronlimab | Chlorotrianisene may increase the thrombogenic activities of Leronlimab. |
| Glembatumumab vedotin | Chlorotrianisene may increase the thrombogenic activities of Glembatumumab vedotin. |
| Olaratumab | Chlorotrianisene may increase the thrombogenic activities of Olaratumab. |
| IPH 2101 | Chlorotrianisene may increase the thrombogenic activities of IPH 2101. |
| TB-402 | Chlorotrianisene may increase the thrombogenic activities of TB-402. |
| Caplacizumab | Chlorotrianisene may increase the thrombogenic activities of Caplacizumab. |
| IMC-1C11 | Chlorotrianisene may increase the thrombogenic activities of IMC-1C11. |
| Eldelumab | Chlorotrianisene may increase the thrombogenic activities of Eldelumab. |
| Lumiliximab | Chlorotrianisene may increase the thrombogenic activities of Lumiliximab. |
| Canakinumab | Chlorotrianisene may increase the thrombogenic activities of Canakinumab. |
| Ipilimumab | Chlorotrianisene may increase the thrombogenic activities of Ipilimumab. |
| Nimotuzumab | Chlorotrianisene may increase the thrombogenic activities of Nimotuzumab. |
| Clenoliximab | Chlorotrianisene may increase the thrombogenic activities of Clenoliximab. |
| Tocilizumab | Chlorotrianisene may increase the thrombogenic activities of Tocilizumab. |
| BIIB015 | Chlorotrianisene may increase the thrombogenic activities of BIIB015. |
| Sonepcizumab | Chlorotrianisene may increase the thrombogenic activities of Sonepcizumab. |
| Motavizumab | Chlorotrianisene may increase the thrombogenic activities of Motavizumab. |
| Elotuzumab | Chlorotrianisene may increase the thrombogenic activities of Elotuzumab. |
| AVE9633 | Chlorotrianisene may increase the thrombogenic activities of AVE9633. |
| Carotuximab | Chlorotrianisene may increase the thrombogenic activities of Carotuximab. |
| XmAb 2513 | Chlorotrianisene may increase the thrombogenic activities of XmAb 2513. |
| Coltuximab ravtansine | Chlorotrianisene may increase the thrombogenic activities of Coltuximab ravtansine. |
| Lucatumumab | Chlorotrianisene may increase the thrombogenic activities of Lucatumumab. |
| Pertuzumab | Chlorotrianisene may increase the thrombogenic activities of Pertuzumab. |
| Siplizumab | Chlorotrianisene may increase the thrombogenic activities of Siplizumab. |
| Apolizumab | Chlorotrianisene may increase the thrombogenic activities of Apolizumab. |
| Sibrotuzumab | Chlorotrianisene may increase the thrombogenic activities of Sibrotuzumab. |
| Bivatuzumab | Chlorotrianisene may increase the thrombogenic activities of Bivatuzumab. |
| Lerdelimumab | Chlorotrianisene may increase the thrombogenic activities of Lerdelimumab. |
| Lexatumumab | Chlorotrianisene may increase the thrombogenic activities of Lexatumumab. |
| Reslizumab | Chlorotrianisene may increase the thrombogenic activities of Reslizumab. |